Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$3.22 +6.6%	$3.84	$2.76 ▼ $6.98	$149.30M	1.21	212,935 shs	213,331 shs
CLNN Clene	$5.66 +6.0%	$3.94	$2.28 ▼ $6.90	$53.35M	0.55	107,222 shs	99,490 shs
IOBT IO Biotech	$1.74 -1.7%	$1.70	$0.66 ▼ $2.79	$116.61M	0.44	8.63 million shs	1.45 million shs
MOLN Molecular Partners	$3.76 +5.9%	$3.68	$3.36 ▼ $7.60	$143.33M	1.1	1,058 shs	2,151 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	+6.62%	+10.27%	-24.06%	-12.50%	-44.00%
CLNN Clene	+5.99%	+56.35%	+51.34%	+138.82%	+9.69%
IOBT IO Biotech	-1.69%	-19.44%	-9.84%	+43.80%	+10.13%
MOLN Molecular Partners	+5.92%	+6.36%	-3.34%	-7.25%	-40.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTMD biote	2.2548 of 5 stars	3.3	2.0	1.1	1.7	1.3
CLNN Clene	3.2603 of 5 stars	3.6	4.0	2.1	2.5	0.6
IOBT IO Biotech	3.3272 of 5 stars	3.7	3.0	3.2	2.5	0.6
MOLN Molecular Partners	2.3705 of 5 stars	3.8	2.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTMD biote	2.50	Moderate Buy	$6.00	86.34% Upside
CLNN Clene	3.17	Buy	$33.00	483.04% Upside
IOBT IO Biotech	3.33	Buy	$8.67	398.08% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	219.15% Upside

Current Analyst Ratings Breakdown

Latest CLNN, BTMD, IOBT, and MOLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
8/18/2025	CLNN Clene	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$83.00 ➝ $48.00
8/14/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
8/12/2025	IOBT IO Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $4.00
8/7/2025	BTMD biote	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$8.00 ➝ $4.00
7/18/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTMD biote	$197.19M	0.81	$0.82 per share	3.94	($1.59) per share	-2.03
CLNN Clene	$340K	166.30	N/A	N/A	($0.86) per share	-6.58
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A
MOLN Molecular Partners	$5.65M	26.87	N/A	N/A	$3.99 per share	0.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTMD biote	$3.16M	$0.90	3.58	5.96	N/A	15.73%	-21.00%	18.26%	11/11/2025 (Estimated)
CLNN Clene	-$39.40M	-$3.76	N/A	N/A	N/A	-10,386.36%	N/A	-125.49%	N/A
IOBT IO Biotech	-$95.49M	-$1.58	N/A	N/A	N/A	N/A	-281.82%	-169.29%	11/11/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	N/A	-42.20%	-38.12%	8/25/2025 (Estimated)

Latest CLNN, BTMD, IOBT, and MOLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	H1 2025	MOLN Molecular Partners	-$0.53	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CLNN Clene	-$0.49	-$0.78	-$0.29	-$0.78	$0.06 million	$0.03 million
8/14/2025	Q2 2025	IOBT IO Biotech	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A
8/6/2025	Q2 2025	BTMD biote	$0.06	$0.10	+$0.04	$0.10	$49.52 million	$48.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTMD biote	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTMD biote	N/A	0.98	0.74
CLNN Clene	N/A	1.58	1.36
IOBT IO Biotech	4.22	1.96	2.32
MOLN Molecular Partners	N/A	15.28	15.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTMD biote	21.68%
CLNN Clene	23.28%
IOBT IO Biotech	54.76%
MOLN Molecular Partners	26.55%

Insider Ownership

Company	Insider Ownership
BTMD biote	24.00%
CLNN Clene	35.30%
IOBT IO Biotech	4.80%
MOLN Molecular Partners	5.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTMD biote	194	49.44 million	37.57 million	Not Optionable
CLNN Clene	100	9.99 million	6.46 million	Optionable
IOBT IO Biotech	30	N/A	N/A	Not Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable

CLNN, BTMD, IOBT, and MOLN Headlines

Recent News About These Companies

Molecular Partners (MOLN) Projected to Post Quarterly Earnings on Monday

2 hours ago | americanbankingnews.com

Molecular Partners appoints Martin Steegmaier as chief scientific officer

August 21 at 11:22 PM | msn.com

Molecular Partners (MOLN) Expected to Announce Earnings on Monday

August 19, 2025 | marketbeat.com

Molecular Partners (NASDAQ:MOLN) Stock Price Down 0.7% - Should You Sell?

August 16, 2025 | marketbeat.com

Molecular Partners AG ADR MOLN (U.S.: Nasdaq) - The Wall Street Journal

August 5, 2025 | wsj.com

Molecular Partners (NASDAQ:MOLN) Stock Price Up 4.3% - Here's Why

July 24, 2025 | marketbeat.com

Molecular Partners AG News (MOLN) - Investing.com

July 2, 2025 | investing.com

Molecular Partners AG (MOLN) - Yahoo Finance

June 26, 2025 | au.finance.yahoo.com

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - Morningstar

June 24, 2025 | morningstar.comM

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

June 22, 2025 | globenewswire.com

Molecular Partners Reports Positive Phase 1/2a Data for MP0533 in Relapsed/Refractory AML at EHA Congress

June 12, 2025 | nasdaq.com $https://www.nasdaq.com/articles/molecular-partners-reports-positive-phase-1-2a-data-mp0533-relapsed-refractory-aml-eha$

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

June 11, 2025 | uk.finance.yahoo.com

Molecular Partners to cut jobs, cash reach now anticipated to extend into 2028

June 10, 2025 | msn.com

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

June 10, 2025 | globenewswire.com

Molecular Partners to Present at Upcoming Investor Conferences

May 19, 2025 | globenewswire.com

Molecular Partners Reports Financial Results and Highlights from Q1 2025

May 15, 2025 | finance.yahoo.com

Molecular Partners presents new data on Radio-DARPin, Switch-DARPin programs

April 26, 2025 | markets.businessinsider.com

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

April 25, 2025 | globenewswire.com

Why Molecular Partners AG’s (MOLN) Stock Is Up 5.04%

April 17, 2025 | aaii.comA

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

April 16, 2025 | globenewswire.com

Dendi and Molecular Lab Partners Announce Strategic Partnership to Empower Labs Nationwide

April 15, 2025 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, BTMD, IOBT, and MOLN Company Descriptions

biote NASDAQ:BTMD

$3.22 +0.20 (+6.62%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.22 0.00 (0.00%)

As of 08/22/2025 04:10 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Clene NASDAQ:CLNN

$5.66 +0.32 (+5.99%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.42 -0.24 (-4.22%)

As of 08/22/2025 07:58 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

IO Biotech NASDAQ:IOBT

$1.74 -0.03 (-1.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.02 (+1.15%)

As of 08/22/2025 07:54 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Molecular Partners NASDAQ:MOLN

$3.76 +0.21 (+5.92%)

Closing price 08/22/2025 03:53 PM Eastern

Extended Trading

$3.88 +0.12 (+3.06%)

As of 08/22/2025 06:38 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time